Evidence map›Paper›PMID 29437631›Full record

ArticleAntimicrobial agents and chemotherapy2018

Short Proline-Rich Lipopeptide Potentiates Minocycline and Rifampin against Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa.

Ronald Domalaon, Yaroslav Sanchak, Linet Cherono Koskei, Yinfeng Lyu, George G Zhanel, Gilbert Arthur, Frank Schweizer

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Effects of Lipidation on a Proline-Rich Antibacterial Peptide.International journal of molecular sciences · 2021
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Ronald DomalaonDepartment of Chemistry, University of Manitoba, Winnipeg, Manitoba, Canada.
Yaroslav SanchakDepartment of Chemistry, University of Manitoba, Winnipeg, Manitoba, Canada.
Linet Cherono KoskeiDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada.
Yinfeng LyuDepartment of Chemistry, University of Manitoba, Winnipeg, Manitoba, Canada.
George G ZhanelDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada.
Gilbert ArthurDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada.
Frank SchweizerDepartment of Chemistry, University of Manitoba, Winnipeg, Manitoba, Canada schweize@cc.umanitoba.ca.ORCID 0000-0001-8697-5519
University of Manitoba · CANortheast Agricultural University · CNUniversity of Nairobi · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of 16 short proline-rich lipopeptides (SPRLPs) were constructed to mimic longer naturally existing proline-rich antimicrobial peptides. Antibacterial assessment revealed that lipopeptides containing hexadecanoic acid (C

Indexed as

Drug Resistance, Multiple, BacterialDrug SynergismHEK293 CellsHep G2 CellsHumansLipopeptidesMicrobial Sensitivity TestsMinocyclineProlinePseudomonas aeruginosaRifampinLipopeptidesMinocyclineProlineRifampinadjuvantlipopeptidesminocyclineproline-rich antimicrobial peptidesPseudomonas aeruginosarifampin

Identifiers

PMID29437631
PMCPMC5914005
OpenAlexW2790887078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.